AI summary · may contain errors
In AMI complicated by cardiogenic shock, cangrelor produced platelet reactivity index <50% in 100% versus 22% with crushed ticagrelor at end of primary PCI.
- 1 cites
Moving in The Lancet.
Rebuilt
AI summary · may contain errors
In AMI complicated by cardiogenic shock, cangrelor produced platelet reactivity index <50% in 100% versus 22% with crushed ticagrelor at end of primary PCI.
Newest first · last 60 days
AI summary · may contain errors
In LIBREXIA-ACS, milvexian added after acute coronary syndrome did not reduce cardiovascular death, myocardial infarction, or ischemic stroke, and showed no intracranial or fatal bleeding increase.
AI summary · may contain errors
In Sweden’s acute coronary syndrome PCI population, a default prasugrel policy did not reduce 1-year ischemic events versus a default ticagrelor policy (11.1% vs 11.8%; adjusted OR 0.90).
AI summary · may contain errors
In an open-label randomized trial of adults ≥70 years on statins for primary prevention, stopping statins was noninferior to continuing at 2 years (−2.0 weeks).
AI summary · may contain errors
In EPIDAURUS, a 1-month DOAC plus potent P2Y12 inhibitor regimen (prasugrel or ticagrelor) in atrial fibrillation plus acute coronary syndrome was linked to higher bleeding rates in 602 enrolled patients.
AI summary · may contain errors
Avatrombopag corrected persistent chemotherapy-induced thrombocytopenia in GI cancer patients, achieving the primary endpoint in 70% versus 17% with placebo.
AI summary · may contain errors
ARC-HBR criteria identify STEMI patients undergoing primary PCI with substantially higher 12-month risk, but do not show a more favorable effect for upfront aspirin omission.
AI summary · may contain errors
Aspirin withdrawal after PCI shows MI odds ratios linked to DAPT duration, with the MI OR dropping below 1.15 from about 90 days.
AI summary · may contain errors
Milvexian added to antiplatelet therapy after acute coronary syndrome does not significantly reduce major adverse cardiovascular events in high-risk patients.
AI summary · may contain errors
Intravenous tirofiban plus aspirin did not significantly reduce early neurological deterioration or new stroke versus aspirin alone in 970 Chinese patients with BAD-related acute ischemic stroke.
Journals this month
Topics moving, week to 17 Nov 2026
By field